Abvc Biopharma (ABVC) Other Operating Expenses (2010 - 2026)
Abvc Biopharma's (ABVC) quarterly Other Operating Expenses came in at $787374.0 in Q1 2026, up 1514.36% YoY from $48773.0 in Q1 2025, and down 43.2% on a QoQ basis from $1.4 million in Q4 2025.
Abvc Biopharma (ABVC) Other Operating Expenses (2010 - 2026) Analysis & Trends
Abvc Biopharma (ABVC) has 14 years of Other Operating Expenses data on file, last reported at $787374.0 in Q1 2026.
- Quarterly Other Operating Expenses rose 1514.36% year-over-year to $787374.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $4.9 million (up 517.43% YoY) and the FY2025 annual result came in at $4.1 million, up 49.37% from the prior year.
- Other Operating Expenses eased to $787374.0 in Q1 2026, from $1.4 million in the prior quarter.
- In the past five years, Other Operating Expenses ranged from a high of $2.0 million in Q1 2024 to a low of -$1.2 million in Q4 2023.
- A 5-year average of $604623.4 and a median of $363079.0 in 2024 frame the typical range for Other Operating Expenses.
- Annual changes were most pronounced in 2023 — Other Operating Expenses tumbled 164.65% — and 2026, when it soared 1514.36%.
- Tracing ABVC's Other Operating Expenses over 5 years: stood at $1.9 million in 2022, then plunged by 164.65% to -$1.2 million in 2023, then soared by 129.66% to $363079.0 in 2024, then surged by 281.79% to $1.4 million in 2025, then slumped by 43.2% to $787374.0 in 2026.
- The last three Other Operating Expenses figures came in at $787374.0 (Q1 2026), $1.4 million (Q4 2025), and $1.1 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Abvc Biopharma | 23.19 Mn | 23.19 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 253,041.00 |
| Mar 31, 2026 | 787,374.00 |
| Dec 31, 2025 | 1.39 Mn |
| Sep 30, 2025 | 1.14 Mn |
| Jun 30, 2025 | 1.57 Mn |
| Mar 31, 2025 | 48,773.00 |
| Dec 31, 2024 | 363,079.00 |
| Sep 30, 2024 | 95,875.00 |
| Jun 30, 2024 | 282,875.00 |
| Mar 31, 2024 | 2.03 Mn |
| Dec 31, 2023 | -1.22 Mn |
| Sep 30, 2023 | 817,740.00 |
| Jun 30, 2023 | 225,740.00 |
| Mar 31, 2023 | 366,489.00 |
| Dec 31, 2022 | 1.89 Mn |
| Sep 30, 2022 | 225,740.00 |
| Jun 30, 2022 | 225,740.00 |
| Mar 31, 2022 | 44,239.00 |
| Dec 31, 2021 | 4.38 Mn |
| Sep 30, 2021 | 225,740.00 |